Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Columbia’s Progesterone Faces FDA Skepticism Over Foreign Data At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.

You may also be interested in...



Watson Hopes Accelerated Approval For Progesterone Gel Remains Option

Company will meet with FDA to determine a path forward now that the agency has issued a “complete response” letter for progesterone vaginal gel 8% for reducing the risk of preterm birth in women with a short cervix, Watson CEO Bisaro says.

Watson Hopes Accelerated Approval For Progesterone Gel Remains Option

Company will meet with FDA to determine a path forward now that the agency has issued a “complete response” letter for progesterone vaginal gel 8% for reducing the risk of preterm birth in women with a short cervix, Watson CEO Bisaro says.

NeurogesX’s Qutenza Potential For Successful Committee Review Hinges On Post Hoc Efficacy Analyses

FDA looks askance at the sponsor’s post hoc analyses showing efficacy for its pain patch (capsaicin 8%) for HIV-associated neuropathic pain 30 minutes after application.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel